215534-63-7

Upstream product

• 109-02-4 4-methyl-morpholine 
• 15761-38-3 L-N-Boc-Ala 
• 17136-36-6 N-benzylglycine 
• 543-27-1 isobutyl chloroformate 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 86666-85-5 N^α-Boc-Ala-N^α-benzylglycine ethyl ester 

Downstream Products

• 215534-65-9 (1-{benzyl-[3-cyano-2-oxo-3-(triphenyl-λ⁵-phosphanylidene)-propyl]-carbamoyl}-ethyl)-carbamic acid tert-butyl ester 
• 261729-76-4 (benzyl-{3-[benzyl-(2-tert-butoxycarbonylamino-propionyl)-amino]-2-oxo-propionyl}-amino)-acetic acid ethyl ester 
• 215534-68-2 2,8-dibenzyl-6-methyl-2,3-dihydro-8H-pyrazino[1,2-a]pyrazine-1,4,7-trione 

Relevant academic research and scientific papers

Design and synthesis of novel conformationally restricted peptide secondary structure mimetics

(matrix presented) A facile synthesis of the novel conformationally restricted reverse turn mimetic is described. The key features are the preparation of the α-keto amide and tandem bicyclic ring formation.

PHOSPHONAMIDATE COMPOUNDS

Phosphonamidates of the formula STR1 wherein X is a substituted or unsubstituted imino or amino acid or ester. These compounds possess angiotensin converting enzyme activity and are thus useful as hypotensive agents.

Phosphonamidate compounds

Phosphonamidates of the formula STR1 wherein X is an amino acid or ester. These compounds possess angiotensin converting enzyme inhibition activity and enkephalinase inhibition activity. Thus they are useful as hypotensive and analgesic agents.